Endoscopic evaluation of the effect of Ulcerone and placebo on duodenal ulcers.
Fifty courses of tripotassium di-citrato bismuthate (Ulcerone) and placebo were administered to ambulant patients with duodenal ulcers in a double-blind trial for 6 weeks. Duodenoscopy was used for initial assessment and to judge improvement. The ulcers of 20 out of 30 patients (67%) healed completely with Ulcerone treatment for 6 weeks, while another 7 patients showed partial improvement. The ulcers of 4 out of 20 patients (20%) on placebo showed healing. The difference is highly significant (chi2 = 20,0; P less than 0,001). Ulcerone is a collodial bismuth substance which is said to act by coating the ulcer by becoming incorporated into granulating tissue at an acid pH. No side-effects of Ulcerone occurred. It is considered to be a safe and effective oral therapeutic substance for ambulant patients with duodenal ulcers.
D000328:Adult; D001729:Bismuth / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000473:pathology; D004386:Duodenum / Q000473:pathology; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D014945:Wound Healing
D001729:Bismuth